9 completed, 2 terminated, 2 unknown. 11 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 8, Terminated 2, Unknown 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow BAY 86-7548: new trials by email Literature Review of BAY 86-7548 trials Research Report on BAY 86-7548
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET/MRI to Stage Prostate Cancer Patients 68Ga-PSMA, 68Ga-RM2 - Prostate Cancer | Phase 2 | Unknown | IRCCS San Raffaele | 50 | 2020-09-09 | 2024-07-03 |
| PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study 68Ga-PSMA, 68Ga-RM2 - Prostate Cancer | Phase 2 | Completed | IRCCS San Raffaele | 60 | 2020-06-03 | 2023-04-10 |
| HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer 68-Ga RM2., 68-Ga PSMA11, PET/MRI - Prostate Cancer | Phase 2 | Terminated | Andrei Iagaru | 4 | 2020-02-05 | 2024-02-01 |
| 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy 68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan - Prostate Cancer | Phase 1 / Phase 2 | Completed | Andrei Iagaru | 14 | 2019-04-09 | 2024-01-30 |
| 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, Positron Emission Tomography - Breast Carcinoma, Estrogen Receptor Positive | Phase 1 / Phase 2 | Completed | Andrei Iagaru | 5 | 2019-03-19 | 2023-12-13 |
| 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer 68Ga RM2, 68Ga-PSMA-11, Investigational PET scanner coils and software - Prostate Cancer | Phase 2 | Completed | Andrei Iagaru | 14 | 2019-01-14 | 2024-01-11 |
| The LightPath® and 68Ga-RM2 in Breast Cancer Study LightPath® Imaging System and 68Ga-RM2, 68Ga-RM2 - Breast Cancer | Phase 3 | Unknown | Lightpoint Medical Limited | 80 | 2018-11-30 | 2018-11-06 |
| 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis - Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma | Phase 2 | Completed | Andrei Iagaru | 44 | 2017-04-10 | 2023-12-12 |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography - Prostate Adenocarcinoma | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 122 | 2015-11-16 | 2023-04-10 |
| 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer 68Ga-RM2 (RM2), PET/CT Scan - Prostate Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 19 | 2015-09-21 | 2021-05-18 |
| PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer [68Ga]RM2, PET/CT - Prostate Cancer | Phase 1 / Phase 2 | Terminated | Lantheus Biosciences Ltd. | 30 | 2015-05-01 | 2017-03-22 |
| 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer 68Ga-DOTA-Bombesin, Magnetic Resonance Imaging (MRI) scan, Positron Emission Tomography (PET) scan - Prostate Carcinoma | Phase 2 | Completed | Stanford University | 10 | 2015-04-01 | 2017-04-11 |
| PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers Bombesin (68Ga) labeled (BAY86-7548) - Diagnostic Imaging | Phase 1 | Completed | Lantheus Biosciences Ltd. | 19 | 2010-11-01 | 2013-01-21 |
Prostatic Neoplasms (8) · Breast Neoplasms (2) · Neoplasms (2) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Neoplasms by Site (1) · Urogenital Neoplasms (1)
Andrei Iagaru (6) · IRCCS San Raffaele (2) · Lantheus Biosciences Ltd. (2) · Lightpoint Medical Limited (1) · Memorial Sloan Kettering Cancer Center (1) · Stanford University (1)
United States (8) · Finland (2) · Italy (2) · Austria (1) · Germany (1) · Switzerland (1) · United Kingdom (1)
Andrei Iagaru (4) · Andrei H Iagaru, MD (3) · Andrew Stephens, MD, PhD (1) · Herbert Vargas Alvarez, MD, PhD (1) · Qamar B Akbar, MSc (1)
PMID 37555901, PMID 26659347, PMID 31478089, PMID 34406051, PMID 36328488, PMID 36396456, PMID 38423030
2008 (1), 2014 (1), P30CA124435 (1), R01CA230438 (1)